Ligand Pharmaceuticals Incorporated (LGND): Rasio rega marang pendapatan

Simbol lan logo merek Ligand Pharma (LGND)

Revenue multiple dynamics amid trade conflicts reveal challenges with international patenting, yet the 24.30 level records fresh values, confirming the resilience of Ligand Pharmaceuticals (LGND). Ligand Pharmaceuticals generates revenue through licensing agreements with partners, creating scientific synergy. Furthermore, the specifics of technology transfer minimize logistical risks, ensuring business stability even amidst macroeconomic instability.

Ligand Pharmaceuticals (LGND): Multiplikator P/S saka 04.07.2022 nganti 16.11.2026

Rincian metrik lan analitis perusahaan Ligand (LGND)

Analisis umum perusahaan:Ligand Pharma (LGND)
Produk mawa merek ligand.com

Assessing asset reliability begins with analyzing the market capitalization to annual revenue ratio, which determines the premium paid per unit of sales. For Ligand Pharmaceuticals (LGND), this calculation confirms the efficiency of a royalty model with minimal costs; therefore, any deviation from historical P/S levels signals either an overvaluation of stable cash flows or an impending price correction.

Karo sapa Ligand Pharmaceuticals saingan

HLN (Haleon) - Rasio kapitalisasi pasar marang pendapatan|Rasio rega marang pendapatan Kenvue Inc KVUE|Verona Pharma Corp - Rasio rega marang pendapatan|MENS: Kapitalisasi marang pendapatan|amneal.com (AMRX) - Kapitalisasi marang pendapatan|Perrigo (PRGO) - Rasio rega marang pendapatan|ALVO (Alvotech S.A.) - Rasio rega marang pendapatan|Kapitalisasi marang pendapatan LQDA|Multiplikator P/S Galapagos Corp|Rasio rega marang pendapatan ANI Pharma (ANIP)|Multiplikator P/S MannKind Corporation (MNKD)|Rasio rega marang pendapatan Amphastar Pharmaceuticals Inc AMPH|Multiplikator P/S Pacira PCRX|ARS Pharmaceuticals Inc - Multiplikator P/S|TBPH - Multiplikator P/S|AQST (Aquestive Therapeutics) - Kapitalisasi marang pendapatan|scPharmaceuticals, Inc. (SCPH) - Multiplikator P/S|Kapitalisasi marang pendapatan TECX|Multiplikator P/S Tonix Pharma|Kapitalisasi marang pendapatan SXTC (SXT Pharmaceuticals)|EPRX: Rasio rega marang dodolan|BioHarvest Sciences - Kapitalisasi marang pendapatan|EXOZ: Rasio kapitalisasi marang pendapatan|ORMP - Rasio rega marang pendapatan|ENTX: Rasio rega marang pendapatan|HYFT: Multiplikator P/S|Kapitalisasi marang pendapatan ABVC BioPharma Inc|CPIX (Cumberland Corp) - Multiplikator P/S|Multiplikator P/S quantumbiopharma.com|Multiplikator P/S FGEN|Kapitalisasi marang pendapatan Telomir Pharmaceuticals, Inc. TELO|Multiplikator P/S RANI (Rani Therapeutics)|SNYR (Synergy CHC Corp) - Rasio rega marang dodolan|RLYB: Kapitalisasi marang pendapatan|lexariabioscience.com (LEXX) - Kapitalisasi marang pendapatan|Pulmatrix Inc (PULM) - Rasio rega marang pendapatan|PTHL: Kapitalisasi marang volume dodolan|APM (Aptorum Group Ltd) - Multiplikator P/S|Lyra Therapeutics Inc (LYRA) - Koefisien rega marang pendapatan|Multiplikator P/S IBO|Kapitalisasi marang volume dodolan TNFA|cbdMD, Inc. - Kapitalisasi marang pendapatan|Rasio kapitalisasi pasar marang pendapatan PRFX|Altamira Therapeutics Ltd. - Multiplikator P/S|LIPO: Rasio rega marang pendapatan|OPTN: Multiplikator P/S|Rasio rega marang dodolan PIRS (Pieris Pharmaceuticals)|PROC (Procaps) - Multiplikator P/S|PTPI (Petros Pharmaceuticals Inc) - Kapitalisasi marang volume dodolan|Multiplikator P/S QLI|SLRN - Rega marang dodolan|Multiplikator P/S TFFP (TFF Pharmaceuticals, Inc)